Medical Marijuana Inc (OTCMKTS:MJNA) reported that its subsidiary HempMeds® Mexico offering Real Scientific Hemp Oil-X was showcased at the 32nd International Congress of Epilepsy from September 2-6, 2017. Dr. Saul Garza, the Mexican pediatric neurologist, presented a poster at the event which outlines his clinical trial using RSHO-X as a treatment method targeting Lennox-Gastaut Syndrome (LGS).

The highlights

Medical Marijuana reported that the trial included 39 subjects with Lennox-Gastaut syndrome, a grave form of pediatric epilepsy that usually develops before the age of 4 years. Of those 39 subjects, which took up to 5-7mg CBD per kg of body weight in increasing doses of RSHO-X™ 5000MG: an average decline of 84% in motor seizures was recorded; 53% of subjects posted better than a 75% decline in seizures; and 17% achieved a complete elimination of seizures over a four-month period. No grave side effects were noted among the patient population.

Dr. Stuart Titus, the CEO of Medical Marijuana, reported that they are excited that Dr. Garza was selected to present his data at the International Congress of Epilepsy as this trial demonstrates their botanical Cannabinoid to offer the best available therapeutic involvement within this epilepsy subject population.

Provided the advanced nature of these conditions, it is quite remarkable that 17% of the LGS patients witnessed a 100% relief from respective seizure episodes. Trials like Dr. Garza’s help show that the therapeutic advantages of botanically-oriented Cannabinoid are real and are assisting fuel increased access to medicinal cannabis programs across the world.

In Mexico, the application of cannabis products for medicinal purposes was particularly vital since when in 2015 the case of Graciela Elizalde Benavides, suffering with Lennox-Gastaut syndrome was undergoing up to 400 seizures daily.

After a legal course accompanied by immense social pressure, the nation’s government approved the therapeutic application with a derivative of cannabis just for this patient, the key milestone for a revolution that enabled Dr. Garza and firms like HempMeds® to offer support for the initiative encouraging access to treatment based on cannabis for a number of patients with several indications.